Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine

Journal of Nanoparticle Research

Volumn 10, Issue 5, 2008, Pages 887-891

  Harivardhan Reddy, L ^a   Ferreira, Humberto ^a   Dubernet, Catherine ^a   Mouelhi, Sinda Lepetre ^b   Desmaële, Didier ^b   Rousseau, Bernard ^c   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ PARIS SUD   (France)

^c DIF   (France)

Author keywords

Absorption; Biodistribution; Colloids; Nanoassemblies; Nanomedicine; Nanoparticles; Oral administration; Squalenoyl gemcitabine, Gemcitabine

Indexed keywords

ABSORPTION; AMPHIPHILES; BIOACCUMULATION; BIOLOGICAL ORGANS; DRUG DELIVERY; TISSUE;

BIODISTRIBUTION; ORAL ADMINISTRATION; SQUALENOYL GEMCITABINE;

MEDICINE;

4 (N) TRISNORSQUALENOYLGEMCITABINE; GEMCITABINE; SQUALENE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; INTESTINE; ISOTOPE LABELING; LIVER; LUNG; MOUSE; NANOMEDICINE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; SPLEEN; STOMACH; THYMUS; TISSUE DISTRIBUTION;

EID: 42549157716     PISSN: 13880764     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11051-007-9322-7     Document Type: Article

References (9)

1. Christman K, Kelsen D, Saltz L et al (1994) Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73:5-7
2. Couvreur P, Stella B, Cattel L et al (2006) Nanoparticules de derives de la gemcitabine. French Patent, WO/2006/090029
3. Couvreur P, Stella B, Reddy LH et al (2006a) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6:2544-2548
4. Hertel LW, Boder GB, Kroin JS et al (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422
5. Kelly GS (1999) Squalene and its potential clinical uses. Altern Med Rev 4:29-36
6. Plunkett W, Huang P, Ghandi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6:7-13
7. Reddy LH, Dubernet C, Lepêtre-Mouelhi S et al (2007) A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 2007, doi: 10.1016/j.jconrel. 2007.08.018
8. Sessa C, Aamdal S, Wolff I et al (1994) Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC early clinical trials group. Ann Oncol 5:471-472
9. 3H-squalene in the rat. Lipids 18:233-238